Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;21(10):1386-1407.
doi: 10.2174/0115672018274038231212105440.

Nanostructured Lipid Carrier-Mediated Transdermal Delivery System of Glibenclamide for Gestational Diabetes: Pharmacokinetic and Pharmacodynamic Evaluation

M Ashwini  1 , Preethi Sudheer  2 , Bharani S Sogali  3
Affiliations

Nanostructured Lipid Carrier-Mediated Transdermal Delivery System of Glibenclamide for Gestational Diabetes: Pharmacokinetic and Pharmacodynamic Evaluation

M Ashwini et al. Curr Drug Deliv. 2024.

Abstract

Background: Gestational diabetes mellitus (GDM) poses significant risks during pregnancy for both mother and fetus. Adherence to oral antidiabetic medications, like glibenclamide (GB), can be challenging, necessitating novel drug delivery methods. Nanostructured lipid carriers (NLC) offer a promising approach by efficiently permeating the skin due to their small size and lipid-based composition.

Objective: This study aimed to develop and evaluate transdermal patches loaded with glibenclamide NLCs to treat GDM.

Methods: Glibenclamide NLCs were prepared using hot homogenization with ultrasonication and melt dispersion method. A central composite design was utilized to optimize the formulations. Transdermal patches containing optimized NLCs were developed using HPMC K 100 and Eudragit L polymers. The patches were evaluated for various parameters, and their pharmacokinetic and pharmacodynamic studies were carried out to assess their safety and efficacy.

Results: Optimized NLCs efficiently permeated rat skin. Cell viability studies indicated the nontoxicity of the formulations. NLC-loaded transdermal patches (F2 and F7) showed drug release of 1098 μg/cm2 and 1001.83 μg/cm2 in 24 h, with a 2.5-fold higher flux and permeation coefficient than the GB patch. Pharmacokinetic analysis revealed Tmax of 8 and 10 h and Cmax of 7127 ng/ml and 7960 ng/ml for F2 and F7, respectively, ensuring sustained drug action. AUC0-α was 625681 ng/ml·h and 363625 ng/ml·h for F2 and F7, respectively, indicating improved bioavailability.

Conclusion: Transdermal patches incorporating NLCs hold promise for enhancing glibenclamide's therapeutic efficacy in GDM treatment. Improved skin permeation, sustained drug release, and enhanced bioavailability make NLC-based transdermal patches a potential alternative with better patient compliance.

Keywords: Glibenclamide; gestational diabetes mellitus; hot homogenization with ultrasonication; melt dispersion technique.; nanostructured lipid carriers.

PubMed Disclaimer

References

    1. Hollander M.H; Paarlberg K.M; Huisjes A.J.M; Gestational diabetes: A review of the current literature and guidelines. Obstet Gynecol Surv 2007,62(2),125-136 - DOI - PubMed
    1. Serlin D.C; Lash R.W; Diagnosis and management of gestational diabetes mellitus. Am Fam Physician 2009,80(1),57-62 - PubMed
    1. Crowther C.A; Hiller J.E; Moss J.R; McPhee A.J; Jeffries W.S; Robinson J.S; Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005,352(24),2477-2486 - DOI - PubMed
    1. Behzadifar S; Barras A; Plaisance V; Pawlowski V; Szunerits S; Abderrahmani A; Boukherroub R; Polymer-based nanostructures for pancreatic beta-cell imaging and non-invasive treatment of diabetes. Pharmaceutics 2023,15(4),1215 - DOI - PubMed
    1. Kalra S; Gupta Y; Kalra B; Singla R; Use of oral anti-diabetic agents in pregnancy: A pragmatic approach. N Am J Med Sci 2015,7(1),6-12 - DOI - PubMed

MeSH terms